Dermatitis
FDA clears investigational new drug application for STAR-0310 for atopic dermatitis
The FDA has cleared the investigational new drug application for STAR-0310 as a potential treatment for atopic dermatitis and other diseases, Astria Therapeutics announced in a press release.
Tapinarof improves itch, sleep quality for children, adults with atopic dermatitis
BOSTON — Daily tapinarof cream 1% improved weekly itch outcomes and sleep in patients with atopic dermatitis and pruritus, according to an abstract presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
Roflumilast may improve atopic dermatitis symptoms, pruritus
BOSTON — Roflumilast cream improved signs and symptoms of atopic dermatitis, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
Upadacitinib effective, mostly safe up to 76 weeks for adolescents with atopic dermatitis
Upadacitinib exhibited efficacy and a favorable benefit-risk profile for the long-term treatment of moderate to severe atopic dermatitis in adolescents, according to a study.
Roflumilast cream 0.15% addresses unmet needs of adults, children with atopic dermatitis
Roflumilast cream 0.15% showed high efficacy rates among patients aged 6 years and older with mild to moderate atopic dermatitis, according to a study.
FDA extends target action date for Vtama cream sNDA for atopic dermatitis
The FDA has extended the target action date of its review of the supplemental new drug application for Vtama cream 1% for the treatment of atopic dermatitis in adults and children aged at least 2 years, Organon announced in a press release.
Vtama cream effective long-term for atopic dermatitis in adult, pediatric patients
Dermavant Sciences presented full results from its long-term extension trial of Vtama cream 1% for the treatment of atopic dermatitis at the Fall Clinical Dermatology Conference, the company announced in a press release.
Adbry shows long-term efficacy in atopic dermatitis
LEO Pharma presented full results from its long-term trial of Adbry for atopic dermatitis at the Fall Clinical Dermatology Conference, according to a company press release.
Tralokinumab shows promise as long-term treatment for head, neck atopic dermatitis
Nearly half of patients with head and neck atopic dermatitis who were treated with tralokinumab reported disease clearance after 9 months, according to a presentation at the European Academy of Dermatology and Venereology Congress.
Plant-based topical improves itch, quality of life among patients with atopic dermatitis
Zabalafin hydrogel clinically improved itch and quality of life among pediatric and adult patients with atopic dermatitis, according to interim results presented at the European Academy of Dermatology and Venerology Congress.